Breast Cancer

7 things to know about the new groundbreaking breast cancer treatment

by Ally Hirschlag

New cancer treatment claims to shrink cancerous tumors in just 11 days

New cancer treatment claims to shrink cancerous tumors in just 11 days

In the past few years alone, medical science has made some great strides when it comes to cancer prevention and treatment — we’ve seen several experimental breast cancer treatments that have been claimed to cure the disease. But it wasn’t until early 2016, when two drugs were used in combination, that the big “cancer cure” seemed like it could become a reality.

At that time, the two drugs, Tykerb (known as Tyverb in Canada) and Herceptin, were already on the market and had been used to treat cancer independently of each other in the past. However, research conducted in England showed that their powers combined might have incredible, cancer-shrinking abilities.

The buzz started in March 2016 when a new study showed the drug combinations’ potential to significantly shrink HER2-positive breast cancer only 11 days after diagnosis. In April 2016, a Lancet study also found the dual-targeted drug therapy to be “active and well-tolerated” among patients with HER2-positive metastatic colorectal cancer. And most recently, in September 2016, an American Association for Cancer Research study confirmed that the two drugs could work as a very active treatment for HER2-positive and hormone receptor-negative breast cancer, when used alongside chemotherapy.

With all the research that’s been released in the past year, here’s what you need to know about this possible game-changing drug therapy:

Next page

About the author


Leave a Comment